ARK Genomic Revolution ETF
ARKG
297 hedge funds and large institutions have $669M invested in ARK Genomic Revolution ETF in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 80 increasing their positions, 94 reducing their positions, and 46 closing their positions.
28% more capital invested
Capital invested by funds: $523M → $669M (+$146M)
7.07% more ownership
Funds ownership: 27.42% → 34.5% (+7.1%)
7% less funds holding
Funds holding: 321 → 297 (-24)
15% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 94
35% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 46
47% less call options, than puts
Call options by funds: $51.8M | Put options by funds: $97.2M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$39.7M |
| 2 |
Citigroup
New York
|
+$33.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$28.5M |
| 4 |
Morgan Stanley
New York
|
+$17.4M |
| 5 |
Goldman Sachs
New York
|
+$7.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$3.45M |
| 2 |
Jane Street
New York
|
-$3.26M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$2.67M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.53M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.22M |
ARKG Hedge Fund Activity: Q1 2023 in Review
297 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2023, worth a combined $669M — up 28% from $523M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ARKG and 30 opened new positions — a net loss of 16 holders — while 94 trimmed existing stakes and 80 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $39.7M. The largest seller was Chevy Chase Trust, exiting entirely with an estimated $3.45M sold.
- 297 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2023, down from 321 in Q4 2022.
- Funds reported $669M of ARK Genomic Revolution ETF stock for Q1 2023, up 28% quarter-over-quarter.
- 30 funds opened new ARK Genomic Revolution ETF positions in Q1 2023 and 46 closed out, a net change of -16 holders.
- The largest ARK Genomic Revolution ETF buyer in Q1 2023 was BNP Paribas Financial Markets, an estimated $39.7M added.
- The largest ARK Genomic Revolution ETF seller in Q1 2023 was Chevy Chase Trust, an estimated $3.45M sold.
Based on aggregated 13F filings for Q1 2023.